Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report

Most patients with advanced renal cancer develop drug resistance to targeted drugs, and the disease progresses with the prolongation of the treatment cycle. Therefore, it is necessary to explore new treatment methods for advanced renal cancer to obtain continuous efficacy and prolong the survival ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Fanjie, Wu, Shuang, Zhang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670338/
https://www.ncbi.nlm.nih.gov/pubmed/34459463
http://dx.doi.org/10.1097/CAD.0000000000001241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670338/
https://www.ncbi.nlm.nih.gov/pubmed/34459463
http://dx.doi.org/10.1097/CAD.0000000000001241

Ejemplares similares